Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA +3.70%77 Return-on-Tangible-Asset is 14.17% as of Mar. 2026, which is 5% above its 10-year median of 13.48. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.10 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 85.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PT Kalbe Farma Tbk's annualizedNet Income for the quarter that ended in Mar. 2026 was €210 Mil. PT Kalbe Farma Tbk's average total tangible assets for the quarter that ended in Mar. 2026 was €1,484 Mil. Therefore, PT Kalbe Farma Tbk's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 14.17%.
The historical rank and industry rank for PT Kalbe Farma Tbk's Return-on-Tangible-Asset or its related term are showing as below:
FRA:LCLA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 10.86 Med: 13.48 Max: 16.39
Current: 12.8
During the past 13 years, PT Kalbe Farma Tbk's highest Return-on-Tangible-Asset was 16.39%. The lowest was 10.86%. And the median was 13.48%.
FRA:LCLA's Return-on-Tangible-Asset is ranked better than 85.42% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.155
vs FRA:LCLA: 12.80
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PT Kalbe Farma Tbk Return-on-Tangible-Asset Related Terms
PT Kalbe Farma Tbk Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.17% mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a Return-on-Tangible-Asset of 14.17% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PT Kalbe Farma Tbk and its competitors. This is near median its historical median of 13.48. Over the past decade, PT Kalbe Farma Tbk's Return-on-Tangible-Asset has ranged from 10.86 to 16.39. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #147 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is PT Kalbe Farma Tbk's Return-on-Tangible-Asset too high?
PT Kalbe Farma Tbk's current Return-on-Tangible-Asset of 14.17% is near median its 10-year median of 13.48. Over the past 10 years, this metric has ranged from a low of 10.86 to a high of 16.39. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. PT Kalbe Farma Tbk's value of 14.17% is 349.1% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #147 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #147 out of 1008 companies for Return-on-Tangible-Asset. This places PT Kalbe Farma Tbk in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. PT Kalbe Farma Tbk's value of 14.17% is 349.1% above this benchmark. Historically, PT Kalbe Farma Tbk's own Return-on-Tangible-Asset has ranged from 10.86 to 16.39 over the past decade. While the company's 10-year median is 13.48 vs. the industry median of 3.16, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current Return-on-Tangible-Asset of 14.17% is 349.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Return-on-Tangible-Asset is 14.17%, which is near median its own 10-year median of 13.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.03 — trading 72% below its estimated fair value. The current Return-on-Tangible-Asset is 14.17%, which is near median its 10-year median of 13.48 and 349.1% above the Drug Manufacturers industry median of 3.16. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Return-on-Tangible-Asset is 14.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 72% below its estimated GF Value™ of €0.10.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Return-on-Tangible-Asset: 14.17% (near median its 10-year median of 13.48)
GF Value™: €0.10 vs. price of €0.03 (72% below fair value)
Industry Position: 349.1% above the Drug Manufacturers median (#147 of 1008)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
